Enrico Vasile
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Enrico Vasile has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
- Alfredo Falcone
University Hospital of Pisa, Pisa, Italy
17 shared publications - Lorenzo Fornaro
Unit of Medical Oncology 2 Azienda Ospedaliero‐Universitaria Pisana Pisa Italy
14 shared publications Silvia Catanese
Azienda Ospedaliero-Universitaria Pisana, Medical Oncology Unit, Department of Translational Research and of New Surgical and Medical Technologies, Pisa, Italy
8 shared publications- Gianna Musettini
U.O. Oncologia Medica II, Azienda Ospedaliero-Universitaria Pisana Istituto Toscano Tumori, Pisa, Italy
7 shared publications - Caterina Vivaldi
Unit of Medical Oncology 2 Azienda Ospedaliero‐Universitaria Pisana Pisa Italy
6 shared publications - Daniele Santini
Medical Oncology, University Campus Bio-Medico, 00128 Roma, Italy
6 shared publications
Latest Publications
- Open Access
Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients
It is increasingly evident the necessity of new predictive tools for the treatment of pancreatic ductal adenocarcinoma in a personalized manner. We present a co-clinical trial testing the predictiveness of zPDX (zebrafish patient-derived xenograft) for assessing if patients could benefit from a therapeutic strategy (ClinicalTrials.gov: XenoZ, NCT03668418). zPDX are generated xenografting tumor tissues in zebrafish embryos. zPDX were exposed to chemotherapy regimens commonly used. We considered a zPDX a responder (R) when a decrease ≥50% in the relative tumor area was reported; otherwise, we considered them a non-responder (NR). Patients were classified as Responder if their own zPDX was classified as an R for the chemotherapy scheme she/he received an adjuvant treatment; otherwise, we considered them a Non-Responder. We compared the cancer recurrence rate at 1 year after surgery and the disease-free survival (DFS) of patients of both groups. We reported a statistically significant higher recurrence rate in the Non-Responder group: 66.7% vs. 14.3% (p = 0.036), anticipating relapse/no relapse within 1 year after surgery in 12/16 patients. The mean DFS was longer in the R-group than the NR-group, even if not statistically significant: 19.2 months vs. 12.7 months, (p = 0.123). The proposed strategy could potentially improve preclinical evaluation of treatment modalities and may enable prospective therapeutic selection in everyday clinical practice.
Open AccessZebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients
It is increasingly evident the necessity of new predictive tools for the treatment of pancreatic ductal adenocarcinoma in a personalized manner. We present a co-clinical trial testing the predictiveness of zPDX (zebrafish patient-derived xenograft) for assessing if patients could benefit from a therapeutic strategy (ClinicalTrials.gov: XenoZ, NCT03668418). zPDX are generated xenografting tumor tissues in zebrafish embryos. zPDX were exposed to chemotherapy regimens commonly used. We considered a zPDX a responder (R) when a decrease ≥50% in the relative tumor area was reported; otherwise, we considered them a non-responder (NR). Patients were classified as Responder if their own zPDX was classified as an R for the chemotherapy scheme she/he received an adjuvant treatment; otherwise, we considered them a Non-Responder. We compared the cancer recurrence rate at 1 year after surgery and the disease-free survival (DFS) of patients of both groups. We reported a statistically significant higher recurrence rate in the Non-Responder group: 66.7% vs. 14.3% (p = 0.036), anticipating relapse/no relapse within 1 year after surgery in 12/16 patients. The mean DFS was longer in the R-group than the NR-group, even if not statistically significant: 19.2 months vs. 12.7 months, (p = 0.123). The proposed strategy could potentially improve preclinical evaluation of treatment modalities and may enable prospective therapeutic selection in everyday clinical practice.
- Open Access
Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM)
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in women (7%) and the sixth in men (5%) in Italy, with a life expectancy of around 5% at 5 years. From 2010, the Italian Association of Medical Oncology (AIOM) developed national guidelines for several cancers. In this report, we report a summary of clinical recommendations of diagnosis, treatment and follow-up of PDAC, which may guide physicians in their current practice. A panel of AIOM experts in upper gastrointestinal cancer malignancies discussed the available scientific evidence supporting the clinical recommendations.
Open AccessClinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM)
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in women (7%) and the sixth in men (5%) in Italy, with a life expectancy of around 5% at 5 years. From 2010, the Italian Association of Medical Oncology (AIOM) developed national guidelines for several cancers. In this report, we report a summary of clinical recommendations of diagnosis, treatment and follow-up of PDAC, which may guide physicians in their current practice. A panel of AIOM experts in upper gastrointestinal cancer malignancies discussed the available scientific evidence supporting the clinical recommendations.
- Open Access
A Model of a Zebrafish Avatar for Co-Clinical Trials
Animal “avatars” and co-clinical trials are being developed for possible use in personalized medicine in oncology. In a co-clinical trial, the cancer cells of the patient’s tumor are xenotransplanted into the animal avatar for drug efficacy studies, and the data collected in the animal trial are used to plan the best drug treatment in the patient trial. Zebrafish have recently been proposed for implementing avatar models, however the lack of a general criterion for the chemotherapy dose conversion from humans to fish is a limitation in terms of conducting co-clinical trials. Here, we validate a simple, reliant and cost-effective avatar model based on the use of zebrafish embryos. By crossing data from safety and efficacy studies, we found a basic formula for estimating the equivalent dose for use in co-clinical trials which we validated in a clinical study enrolling 24 adult patients with solid cancers (XenoZ, NCT03668418).
Open AccessA Model of a Zebrafish Avatar for Co-Clinical Trials
Animal “avatars” and co-clinical trials are being developed for possible use in personalized medicine in oncology. In a co-clinical trial, the cancer cells of the patient’s tumor are xenotransplanted into the animal avatar for drug efficacy studies, and the data collected in the animal trial are used to plan the best drug treatment in the patient trial. Zebrafish have recently been proposed for implementing avatar models, however the lack of a general criterion for the chemotherapy dose conversion from humans to fish is a limitation in terms of conducting co-clinical trials. Here, we validate a simple, reliant and cost-effective avatar model based on the use of zebrafish embryos. By crossing data from safety and efficacy studies, we found a basic formula for estimating the equivalent dose for use in co-clinical trials which we validated in a clinical study enrolling 24 adult patients with solid cancers (XenoZ, NCT03668418).
- Open Access
Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study
Early tumor shrinkage (ETS) and depth of response (DoR) predict favorable outcomes in metastatic colorectal cancer. We aim to evaluate their prognostic role in metastatic pancreatic cancer (PC) patients treated with first-line modified-FOLFIRINOX (FOLFOXIRI) or Gemcitabine + Nab-paclitaxel (GemNab). Hence, 138 patients were tested for ETS, defined as a ≥20% reduction in the sum of target lesions’ longest diameters (SLD) after 6–8 weeks from baseline, and DoR, i.e., the maximum percentage shrinkage in the SLD from baseline. Association of ETS and DoR with progression-free survival (PFS) and overall survival (OS) was assessed. ETS was reached in 49 patients (39.5% in the FOLFOXIRI, 29.8% in the GemNab group; p = 0.280). In the overall population, ETS was significantly associated with better PFS (8.0 vs. 4.8 months, p < 0.001) and OS (13.2 vs. 9.7 months, p = 0.001). Median DoR was −27.5% (−29.4% with FOLFOXIRI and −21.4% with GemNab, p = 0.016): DoR was significantly associated with better PFS (9.0 vs. 6.7 months, p < 0.001) and OS (14.3 vs. 11.1 months, p = 0.031). Multivariate analysis confirmed both ETS and DoR are independently associated with PFS and OS. In conclusion, our study added evidence on the role of ETS and DoR in the prediction of outcome of PC patients treated with first-line combination chemotherapy.
Open AccessEarly Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study
Early tumor shrinkage (ETS) and depth of response (DoR) predict favorable outcomes in metastatic colorectal cancer. We aim to evaluate their prognostic role in metastatic pancreatic cancer (PC) patients treated with first-line modified-FOLFIRINOX (FOLFOXIRI) or Gemcitabine + Nab-paclitaxel (GemNab). Hence, 138 patients were tested for ETS, defined as a ≥20% reduction in the sum of target lesions’ longest diameters (SLD) after 6–8 weeks from baseline, and DoR, i.e., the maximum percentage shrinkage in the SLD from baseline. Association of ETS and DoR with progression-free survival (PFS) and overall survival (OS) was assessed. ETS was reached in 49 patients (39.5% in the FOLFOXIRI, 29.8% in the GemNab group; p = 0.280). In the overall population, ETS was significantly associated with better PFS (8.0 vs. 4.8 months, p < 0.001) and OS (13.2 vs. 9.7 months, p = 0.001). Median DoR was −27.5% (−29.4% with FOLFOXIRI and −21.4% with GemNab, p = 0.016): DoR was significantly associated with better PFS (9.0 vs. 6.7 months, p < 0.001) and OS (14.3 vs. 11.1 months, p = 0.031). Multivariate analysis confirmed both ETS and DoR are independently associated with PFS and OS. In conclusion, our study added evidence on the role of ETS and DoR in the prediction of outcome of PC patients treated with first-line combination chemotherapy.
- 1 June 2018
- Published by Elsevier in Pancreatology
- Vol. 18 (4) , S123-S124
Ampullary adenocarcinomas: The immunohistochemical score of CDX2, CK7 and CK 20 identify pathological subtypes and their prognosis
- 1 June 2018
- Published by Elsevier in Pancreatology
- Vol. 18 (4) , S123-S124
Ampullary adenocarcinomas: The immunohistochemical score of CDX2, CK7 and CK 20 identify pathological subtypes and their prognosis
- 1 June 2018
- Published by Elsevier in Pancreatology
- Vol. 18 (4) , S129
Analysis of tumor response in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX or Gemcitabine + Nab-Paclitaxel
- 1 June 2018
- Published by Elsevier in Pancreatology
- Vol. 18 (4) , S129
Analysis of tumor response in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX or Gemcitabine + Nab-Paclitaxel
- 1 April 2018
- Published by AME Publishing Company in Annals of Pancreatic Cancer
- Vol. 1 (1) , AB076
AB076. P048. Microsatellite instability and tumor volume inversely affect early progression free survival in adjuvant setting of patients with pancreatic ductal adenocarcinoma: lights and shadows of molecular pathology and immunotherapy
Background: Pancreatic ductal adenocarcinoma (PDAC) may present microsatellite instability (MSI), phenotype related to a damage of DNA mismatch repair (MMR) system. The MSI-driven cancer pathway leads to the synthesis of aberrant and potentially immunogenic neo-antigens by the tumor cells. Immunotherapy with ICK inhibitors has recently constituted a source of personalized treatment for MSI cancer patients and support the evaluation of MSI phenotype in PDAC. The aim of this study is to evaluate MSI in PDAC patients presenting metastatic pathology after pancreatic resection featuring first line of chemotherapy in order to evaluate a possible immunotherapy treatment. Methods: Ten patients affected by metastatic PDAC after surgical resection and adjuvant chemotherapy with curative intent were selected for MSI analyses. Immunohistochemistry (IHC) evaluations for genes MLH1, MSH2, MSH6 and PMS2 were performed. We assessed MSI when at the least 30% of selected markers lost their protein expression. Pathological data of primary tumor were assessed consulting VIII edition of TNM and the size of tumor was evaluated as volume (cm3). Clinical data, progression free survival (PFS) and overall survival (OS) were obtained by Long-Rank tests. Results: The mean follow-up was 19.02 months and the living patients were 70% (7/10). The median PFS and OS were 7.51 and 23.02 months, respectively. All patients showed a microsatellite stability, in which no alteration of protein expression in MMR system was found. Indeed, nobody was treated with immunotherapy. We identified 2 different groups (5 patients each), based on their early (E) or late (L) metastatic pathology (less or more 6 months after surgery), respectively. Furthermore, we found a significant difference in terms of PFS between these 2 groups (E vs. L; 2.20 vs. 14.63; HR =4.644; 95% CI, 3.982–103.200; P=0.0018). Nevertheless, we found significant differences comparing E vs. L group in terms of mean tumor score (2.780 vs. 1.870; P=0.0067) and volume (88.68 vs. 8.30; P=0.0068). No significant difference in term of OS were observed. Conclusions: Our results confirmed that MMR/MSI alterations are very rare or absent in PDAC patients. This fact represents a limit in order to submit the PDAC patients to immunotherapy clinical trials. It’s not still clear whether MSI pathways might be involved in early metastatic process of PDAC. Nevertheless, we showed that both tumor scoring and volume could play a pivotal role in early recurrence of pathology.
- 1 April 2018
- Published by AME Publishing Company in Annals of Pancreatic Cancer
- Vol. 1 (1) , AB076
AB076. P048. Microsatellite instability and tumor volume inversely affect early progression free survival in adjuvant setting of patients with pancreatic ductal adenocarcinoma: lights and shadows of molecular pathology and immunotherapy
Background: Pancreatic ductal adenocarcinoma (PDAC) may present microsatellite instability (MSI), phenotype related to a damage of DNA mismatch repair (MMR) system. The MSI-driven cancer pathway leads to the synthesis of aberrant and potentially immunogenic neo-antigens by the tumor cells. Immunotherapy with ICK inhibitors has recently constituted a source of personalized treatment for MSI cancer patients and support the evaluation of MSI phenotype in PDAC. The aim of this study is to evaluate MSI in PDAC patients presenting metastatic pathology after pancreatic resection featuring first line of chemotherapy in order to evaluate a possible immunotherapy treatment. Methods: Ten patients affected by metastatic PDAC after surgical resection and adjuvant chemotherapy with curative intent were selected for MSI analyses. Immunohistochemistry (IHC) evaluations for genes MLH1, MSH2, MSH6 and PMS2 were performed. We assessed MSI when at the least 30% of selected markers lost their protein expression. Pathological data of primary tumor were assessed consulting VIII edition of TNM and the size of tumor was evaluated as volume (cm3). Clinical data, progression free survival (PFS) and overall survival (OS) were obtained by Long-Rank tests. Results: The mean follow-up was 19.02 months and the living patients were 70% (7/10). The median PFS and OS were 7.51 and 23.02 months, respectively. All patients showed a microsatellite stability, in which no alteration of protein expression in MMR system was found. Indeed, nobody was treated with immunotherapy. We identified 2 different groups (5 patients each), based on their early (E) or late (L) metastatic pathology (less or more 6 months after surgery), respectively. Furthermore, we found a significant difference in terms of PFS between these 2 groups (E vs. L; 2.20 vs. 14.63; HR =4.644; 95% CI, 3.982–103.200; P=0.0018). Nevertheless, we found significant differences comparing E vs. L group in terms of mean tumor score (2.780 vs. 1.870; P=0.0067) and volume (88.68 vs. 8.30; P=0.0068). No significant difference in term of OS were observed. Conclusions: Our results confirmed that MMR/MSI alterations are very rare or absent in PDAC patients. This fact represents a limit in order to submit the PDAC patients to immunotherapy clinical trials. It’s not still clear whether MSI pathways might be involved in early metastatic process of PDAC. Nevertheless, we showed that both tumor scoring and volume could play a pivotal role in early recurrence of pathology.
- 1 April 2018
- Published by AME Publishing Company in Annals of Pancreatic Cancer
- Vol. 1 (1) , AB046
AB046. P017. Identification of pathological ampullary adenocarcinomas subtypes and their prognosis using the immunohistochemical score of CDX2, CK7 and CK 20
Background: Ampullary adenocarcinomas (AACs) are heterogeneous and numerous methods of categorization histological subtypes exist. Histology phenotype based on immunohistochemistry (IHC) of caudal-type homeodomain transcription factor 2 (CDX2) and Cytokeratins (CK7 and CK20) staining has been tested in order to identify three most important sub-classes: intestinal (INT), pancreato-biliary (PB) and mixed-type (MT). The identification of MT tumors is often difficult with conventional histology and its clinical outcome is unclear. We attempt to identify only two subtypes in AACs samples, using an IHC score based-on CDX2, CK7 and CK20 evaluation on AAC samples. Methods: Tissue samples from 20 patients with resected AAC were arranged on tissue microarrays (TMA) platform and their classification was obtained by histology and IHC expression of CDX2, CK7 and CK 20. IHC score was obtained for each marker summing the number of positive cells (0: no stained cells; 1: Results: Histological parameters defined AAC subtype samples as follows: 15% INT, 45% PB and 40% MT. Using the IHC expression and the GS, 75% and 25% of MT samples were assigned to INT and PB, respectively. The mean value of GS was 9.5 (range, 4.0–16.0). All INT samples had a GS over the mean, while all PB sample had a global score under the mean (P=0.0011). In particular, the INT samples are identified by high expression of CDX2 and CK20, while PB samples showed high expression of CK7 and negative expression of CK20 (P=0.0008). The overall survival (OS) of molecular intestinal histomolecular phenotype (INT) vs. PB phenotype showed significant differences (85.7 vs. 20.3 months; HR, 8.39; 95% CI, 1.38–18.90; P=0.0152). Conclusions: Histopathologic and molecular criteria combination define clinically relevant histomolecular phenotypes of AACs and potentially represent distinct diseases with significant implications for current therapeutic strategies.
- 1 April 2018
- Published by AME Publishing Company in Annals of Pancreatic Cancer
- Vol. 1 (1) , AB046
AB046. P017. Identification of pathological ampullary adenocarcinomas subtypes and their prognosis using the immunohistochemical score of CDX2, CK7 and CK 20
Background: Ampullary adenocarcinomas (AACs) are heterogeneous and numerous methods of categorization histological subtypes exist. Histology phenotype based on immunohistochemistry (IHC) of caudal-type homeodomain transcription factor 2 (CDX2) and Cytokeratins (CK7 and CK20) staining has been tested in order to identify three most important sub-classes: intestinal (INT), pancreato-biliary (PB) and mixed-type (MT). The identification of MT tumors is often difficult with conventional histology and its clinical outcome is unclear. We attempt to identify only two subtypes in AACs samples, using an IHC score based-on CDX2, CK7 and CK20 evaluation on AAC samples. Methods: Tissue samples from 20 patients with resected AAC were arranged on tissue microarrays (TMA) platform and their classification was obtained by histology and IHC expression of CDX2, CK7 and CK 20. IHC score was obtained for each marker summing the number of positive cells (0: no stained cells; 1: Results: Histological parameters defined AAC subtype samples as follows: 15% INT, 45% PB and 40% MT. Using the IHC expression and the GS, 75% and 25% of MT samples were assigned to INT and PB, respectively. The mean value of GS was 9.5 (range, 4.0–16.0). All INT samples had a GS over the mean, while all PB sample had a global score under the mean (P=0.0011). In particular, the INT samples are identified by high expression of CDX2 and CK20, while PB samples showed high expression of CK7 and negative expression of CK20 (P=0.0008). The overall survival (OS) of molecular intestinal histomolecular phenotype (INT) vs. PB phenotype showed significant differences (85.7 vs. 20.3 months; HR, 8.39; 95% CI, 1.38–18.90; P=0.0152). Conclusions: Histopathologic and molecular criteria combination define clinically relevant histomolecular phenotypes of AACs and potentially represent distinct diseases with significant implications for current therapeutic strategies.